GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (NAS:RVMD) » Definitions » Valuation Rank

RVMD (Revolution Medicines) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Revolution Medicines Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Revolution Medicines Valuation Rank Related Terms

Thank you for viewing the detailed overview of Revolution Medicines's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Revolution Medicines Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (NAS:RVMD) » Definitions » Valuation Rank
Comparable Companies
XENE IBRX CRNX NTLA PRTA CBAY BHVN NMRA RCKT ACLX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
42Z:Germany
Address
700 Saginaw Drive, Redwood City, CA, USA, 94063
Website
https://www.revmed.com
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Executives
Jeff Cislini officer: General Counsel C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Stephen Michael Kelsey officer: See Remarks C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Mark A Goldsmith director, officer: See Remarks 925 PAGE MILL ROAD, PALO ALTO CA 94304
Sushil Patel director C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Margaret A Horn officer: See Remarks 925 PAGE MILL ROAD, PALO ALTO CA 94304
Jack Anders officer: Chief Financial Officer C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Barbara Weber director C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Xiaolin Wang officer: See Remarks C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Thilo Schroeder director C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Lorence H. Kim director C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Third Rock Ventures Iii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Flavia Borellini director C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Third Rock Ventures Ii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Peter Svennilson director, 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Vincent A. Miller director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139